MITF and neoplasm: It was revealed that systemic targeting of MITF by nelfinavir led to a prominent delay of tumor growth, and targeting MITF was capable of potentiating the treatment influence of anti-PD-1 antibodies that could be reversed by liproxstatin-1, as was revealed by both tumor weight and tumor volume (Figure 6f–h).